2-[7-[4-[(4-imidazo[1,2-a]pyridin-3-yl-5-methyl-pyrimidin-2-yl)amino]-3-methoxy-phenyl]-9-oxa-3,7-diazabicyclo[3.3.1]nonan-3-yl]ethanol | 1224706-39-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 2-[7-[4-[(4-imidazo[1,2-a]pyridin-3-yl-5-methyl-pyrimidin-2-yl)amino]-3-methoxy-phenyl]-9-oxa-3,7-diazabicyclo[3.3.1]nonan-3-yl]ethanol
• 英文别名: 2-[7-[4-[(4-Imidazo[1,2-a]pyridin-3-yl-5-methylpyrimidin-2-yl)amino]-3-methoxyphenyl]-9-oxa-3,7-diazabicyclo[3.3.1]nonan-3-yl]ethanol
• CAS: 1224706-39-1
• 化学式: C₂₇H₃₁N₇O₃
• 分子量: 501.588
• InChiKey: NWVGITIFYKEHIT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  37
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  100
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• NOVEL COMPOUNDS 515
  申请人：Ducray Richard

  公开号：US20100105655A1

  公开（公告）日：2010-04-29

  There is provided novel pyrimidine derivatives of formula (I) or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  提供了化学式（I）的新型嘧啶衍生物或其药用盐，以及它们的制备方法、含有它们的药物组合物以及它们在治疗中的应用。
• [EN] PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS<br/>[FR] PYRAZOLO ET IMIDAZO-PYRIDINYL-PYRIMIDINAMINES UTILISÉS COMME INHIBITEURS DE LA TYROSINE KINASE IGF-1R
  申请人：ASTRAZENECA AB

  公开号：WO2010049731A1

  公开（公告）日：2010-05-06

  There is provided novel pyrimidine derivatives of formula (I) or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
• [EN] DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS<br/>[FR] INHIBITEURS DE DIACYLGLYCÉROL ACYLTRANSFÉRASE
  申请人：VIA PHARMACEUTICALS INC

  公开号：WO2010056506A1

  公开（公告）日：2010-05-20

  Provided herein are compounds of the formula (I): were Rl is phenyl, R2 is hyrogen, halogen or lower alkyl,X is carbon on nitrogen, and R3 is isoquinoline, -amino, or a-4- to 6-membered heterocycloalkyl ring and pharmaceutically acceptable salts thereof, which are active as DGAT inhibitors and therefore find uses in treatment of diseases associated with abnormal metabolism of triglicerides, such as, for example, obesity, type Il diabetes mellitus and metabolic syndrome.